



Madrigal

Join us for an engaging sponsored symposium at ECO 2026

Thursday 14 May, 13:45–15:15 TRT

Hall 2

MASH in People Living with Obesity: Pathophysiology, Risk Stratification and Optimised Management

Expert speakers



Prof. Amalia Gastaldelli



Prof. Cyrielle Caussy



Dr Paul Brennan

Learning objectives

- Explain the biological mechanisms linking obesity to progressive liver fibrosis in MASH
- Recognise which patients require hepatology referral and liver-directed therapy, beyond lifestyle interventions and anti-obesity pharmacotherapy
- Apply a stepwise, guideline-aligned non-invasive testing strategy to identify patients with moderate-to-advanced fibrosis in obesity clinics
- Integrate MASH management into multidisciplinary obesity care pathways

MED-GL-DS-2600006 | Date of preparation: March 2026

This is a Madrigal Pharmaceuticals-sponsored symposium at the 33rd European Congress on Obesity (ECO) intended for healthcare professionals. MASH, metabolic dysfunction-associated steatohepatitis.